Lisa Henderson

New models such as IROs are changing the way industry views the current site landscape and addressing challenges.

Innovative pharma companies are stepping up to integrate digital health technology to advance pharmaceutical drug and medical device development, in both the healthcare and research worlds, to achieve better measurements and outcomes.

In this exclusive Q&A with Applied Clinical Trials, Janice Chang, CEO of TransCelerate BioPharma, provides an inside look into her career journey, her work at the company, how the industry has changed in the last 10 years, as well as her thoughts on where the industry should put its efforts in clinical trials.

Agency provides update on decentralized trials and digital health technologies at DIA 2023.

The evolution of data and digital health uses in both the healthcare and research worlds is bringing the two closer together for the good of patients.

"What does the general public not understand the most about clinical trials?" is the question we posed to three industry professionals at DIA 2023.

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants.

From startups to major research organizations, early-phase research can be managed in different ways depending on the company.

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved.

CDER and CBER leaders update initiatives in the rare disease space within the past year.

The many sources of data source in clinical trials can be overwhelming, but the data itself can be used positively to guide clinical operations decision-making.

Sponsors offers patient and caregiver insights on hybrid and decentralized clinical trial design provided by their feedback processes.

DIA session offers an overview of the current regulatory landscape and challenges for both sponsors and regulators in achieving quality and integrity in the fast-moving area.

Jennifer Duff, General Manager, Zelta Clinical Trials Solutions, Merative (formerly IBM Watson Health), discusses her leadership philosophy, major technological changes are impacting clinical trials operations professionals today and in the future, plus much more.

Newly released book edited by Matt Reaney, (PhD, CPsychol, CSci, MSc), head, science and analytics, PCS, at IQVIA focuses on patient experience data with all levels of clinical research in mind.

Insights from KOLs at the mid-May CRAACO event.

Chris Learn, PhD, PMP, Vice President, Cell and Gene Therapy Center of Excellence, Parexel describes highlights of his career, what originally spurred his interest in clinical research, the current landscape of CGTs and much more.

Doug Warner, MD and CMO for eFFECTOR Therapeutics, discusses the complexities of oncology clinical trials, the important relationship medical directors should have with their clinical study teams, and more.

Insights from recent industry events clear path for companies to identify how their internal practices could be harming the environment.

Peter Benton, President and CO-CEO for Worldwide Clinical Trials, speaks about his unconventional entrance into the industry, advice for clinops professionals, and much more.

Panel discusses what real-world evidence—and related patient-reporting technology—need to achieve to better influence payer decision-making.

Identifying key differences between PV and drug safety.

Panel finds potential drug rule difficult to manage.

Rose Blackburne, MD, MBA, Vice President, Global Head, General Medicine, PPD Clinical Research, Thermo Fisher and Margarita Nunez, MD, Principal Investigator, Synexus NY / Accelerated Enrollment Solutions New York discuss their panel at the recent Health Equity in Clinical Trials Congress in Boston last month; share insights into how diversity can be improved at the site and CRO; and the hope that clinical trial awareness and diversity can be discussed with all levels of stakeholders in healthcare to improve drug development worldwide.

Ira C. Spector, PhD, MBA, CEO and Co-Founder, SFA Therapeutics discusses how his career journey has epitomized the ability to solve problems, which is essentially the role of drug development. It has also led to the formation and strategic approach to his company’s early-stage clinical trials for using the microbiome to address chronic inflammatory diseases.

Panel discussion at SCOPE highlights strategies to increase diversity in clinical trials.

Noise in modern day life may be interfering with our ability to learn.

Beth MacEntee Pileggi, Head of Global Case and Safety Data Management with Janssen Pharmaceuticals of Johnson & Johnson, and Co-Lead of TransCelerate’s Pharmacovigilance Agreements Optimization Initiative, discusses the importance of safety, collaboration, TransCelerate’s positive role in the pharma industry and her passion for PV.